Database Member Home
RAS Member Home
In an increasingly crowded US oncology market, it is imperative for bio-pharma companies to plan and execute their oncology portfolio launches seamlessly.
This Best Practices LLC's study equips oncology launch teams with evidence-based benchmarks around investment, staffing and timing requirements to successfully launch new oncology drugs in the U.S. market.
For further launch related queries, please contact: email@example.com or firstname.lastname@example.org
Pharmaceutical companies launching an oncology product in the United States often face crowded markets and regulatory constraints... (ID PSM-341)
Read More »
The objective of this benchmarking study is to help biopharma leaders develop competitive launch and pre-launch activity budgets to ensure successful U... (ID PSM-326)
In today’s pharmaceutical industry–where the recent product launch landscape is marked by as many failures as successes—it is critical for launch teams to understand the right level of resources required to give each new product its best chance for gaining a market foothold... (ID PSM-262)